Concepedia

Marchessini Casibang

MC

Statistics

Publications

8

Citations

288

H-Index

8

Active since

1999

Affiliations

National Cancer Institute(Current)

Washington University Medical Center

George Washington University

National Institute of Diabetes and Digestive and Kidney Diseases

Tulane University

Marchessini Casibang is an author at National Cancer Institute specializing in oncology, cell signaling, and signal transduction.

Publications per year

1999–2002

8

Publications

8

SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells

Terry W. Moody, Jessica Chiles, Marchessini Casibang et al. · Peptides · 2001 · 61 citations

, , +9

Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells

Marchessini Casibang, Sally Purdom, Sonia B. Jakowlew et al. · Lung Cancer · 2001 · 57 citations

, , +13

PACAP (6–38) is a PACAP receptor antagonist for breast cancer cells

Julius Leyton, Yehoshua Gozes, Joseph R. Pisegna et al. · Breast Cancer Research and Treatment · 1999 · 43 citations

, , +8

A bombesin receptor subtype-3 peptide increases nuclear oncogene expression in a MEK-1 dependent manner in human lung cancer cells

H. Christian Weber, James W. Walters, Julius Leyton et al. · European Journal of Pharmacology · 2001 · 33 citations · Full text

, , +7

VPAC<sub>1</sub>Receptors and Lung Cancer

Terry W. Moody, Jamie L. Walters, Marchessini Casibang et al. · Annals of the New York Academy of Sciences · 2000 · 29 citations · Full text

, , +12

1–5 of 8